董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yang Lu | 男 | Chief Executive Officer, Chairman of the Board | 43 | 未披露 | 3913.00 | 2023-09-29 |
| Ping Ji | 女 | Director | 59 | 未披露 | 未持股 | 2023-09-29 |
| Lars Erik Birgerson | 男 | Director, President, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary | 70 | 未披露 | 未持股 | 2023-09-29 |
| Shaorong Liu | 男 | Independent Director | 45 | 未披露 | 未持股 | 2023-09-29 |
| Ming Lun Alan Tse | 男 | Independent Director | 43 | 未披露 | 未持股 | 2023-09-29 |
| Cheguo Cai | 男 | Independent Director | 46 | 未披露 | 未持股 | 2023-09-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yang Lu | 男 | Chief Executive Officer, Chairman of the Board | 43 | 未披露 | 3913.00 | 2023-09-29 |
| Lars Erik Birgerson | 男 | Director, President, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary | 70 | 未披露 | 未持股 | 2023-09-29 |
| Kaiyang Tang | 男 | Senior Vice President, Global Head of Clinical Operatios | 59 | 未披露 | 未持股 | 2023-09-29 |
| Wei Zhang | 女 | Chief Financial Officer | 32 | 未披露 | 未持股 | 2023-09-29 |
| Victoria Elizabeth Demby | 女 | Senior Vice President, Global Head of Regulatory Affairs | 53 | 未披露 | 未持股 | 2023-09-29 |
董事简历
中英对照 | 中文 | 英文- Yang Lu
-
杨璐是Adlai Nortye Ltd.集团的联合创始人，自2006年起担任Adlai Nortye Ltd.董事。目前，他还担任Adlai Nortye有限公司首席执行官和Adlai Nortye有限公司董事会主席。卢先生在制药行业有20年的经验。在创立Adlai Nortye有限公司之前，卢先生于2003年4月至2004年3月在Hybio制药有限公司工作。卢先生于2002年7月获得厦门大学生物技术学士学位，并于2012年9月获得中欧国际工商学院EMBA-Executive工商管理硕士学位。
Yang Lu,co-founded Adlai Nortye Ltd. group and has served as Adlai Nortye Ltd. director since 2006. Currently he also serves as Adlai Nortye Ltd. chief executive officer and the chairman of Adlai Nortye Ltd. board of directors. Mr. Lu has 20 years of experience in the pharmaceutical industry. Prior to founding Adlai Nortye Ltd. company, Mr. Lu worked at Hybio Pharmaceutical Co., Ltd from April 2003 to March 2004. Mr. Lu obtained his bachelor's degree in biotechnology from Xiamen University in July 2002, and his EMBA-Executive Master of Business Administration from China Europe International Business School in September 2012. - 杨璐是Adlai Nortye Ltd.集团的联合创始人，自2006年起担任Adlai Nortye Ltd.董事。目前，他还担任Adlai Nortye有限公司首席执行官和Adlai Nortye有限公司董事会主席。卢先生在制药行业有20年的经验。在创立Adlai Nortye有限公司之前，卢先生于2003年4月至2004年3月在Hybio制药有限公司工作。卢先生于2002年7月获得厦门大学生物技术学士学位，并于2012年9月获得中欧国际工商学院EMBA-Executive工商管理硕士学位。
- Yang Lu,co-founded Adlai Nortye Ltd. group and has served as Adlai Nortye Ltd. director since 2006. Currently he also serves as Adlai Nortye Ltd. chief executive officer and the chairman of Adlai Nortye Ltd. board of directors. Mr. Lu has 20 years of experience in the pharmaceutical industry. Prior to founding Adlai Nortye Ltd. company, Mr. Lu worked at Hybio Pharmaceutical Co., Ltd from April 2003 to March 2004. Mr. Lu obtained his bachelor's degree in biotechnology from Xiamen University in July 2002, and his EMBA-Executive Master of Business Administration from China Europe International Business School in September 2012.
- Ping Ji
-
Ji Ping，担任Adlai Nortye Ltd.董事，自本次发行完成后生效。她在生物制药药物开发方面拥有超过25年的经验。自2017年7月起，季博士在美国协和麒麟有限公司担任全球安全负责人。在此之前的2011年8月至2017年7月，她在美国拜耳医药保健公司担任全球安全负责人。Ji博士还曾于2006年12月至2011年7月担任美国泰和公司的医疗安全主管，于2004年6月至2006年12月担任美国百时美施贵宝公司的医疗审查员，并于2002年9月至2004年6月担任美国赛诺菲公司的临床科学家。在此之前，从2000年9月至2002年9月，她在辉瑞公司担任临床科学家。1993年5月，Ji博士从罗格斯大学新布朗斯威克研究生院、新泽西州立大学和美国罗伯特·伍德·约翰逊医学院生物医学科学研究生院联合提供的细胞生物学课程中获得了医学硕士学位。1986年8月，她在中国首都医学研究院获得医学博士学位。
Ping Ji,serve as Adlai Nortye Ltd. director effective upon the completion of this offering. She has over 25 years of experience in biopharmaceutical drug development. Since July 2017, Dr. Ji served as the global safety leader at Kyowa Kirin Co., Ltd. in the United States. Before that, from August 2011 to July 2017, she served as the global safety leader at Bayer HealthCare Pharmaceuticals Inc. in the United States. Dr. Ji has also served as the medical safety lead at Taiho in the United States from December 2006 to July 2011, as a medical reviewer at Bristol-Myers Squibb Company in the United States from June 2004 to December 2006, and as a clinical scientist at Sanofi S.A. in the United States from September 2002 to June 2004. Prior to that, from September 2000 to September 2002, she worked as a clinical scientist at Pfizer Corporation. Dr. Ji obtained her master of medicine from the cell biology program offered jointly by Graduated School-New Brunswick at Rutgers, the state University of New Jersey and the UMDNJ-Graduate School of Biomedical Sciences at Robert Wood Johnson Medical School in the United States in May 1993. She obtained her doctor of medicine from Capital Institute of Medicine in the PRC in August 1986. - Ji Ping，担任Adlai Nortye Ltd.董事，自本次发行完成后生效。她在生物制药药物开发方面拥有超过25年的经验。自2017年7月起，季博士在美国协和麒麟有限公司担任全球安全负责人。在此之前的2011年8月至2017年7月，她在美国拜耳医药保健公司担任全球安全负责人。Ji博士还曾于2006年12月至2011年7月担任美国泰和公司的医疗安全主管，于2004年6月至2006年12月担任美国百时美施贵宝公司的医疗审查员，并于2002年9月至2004年6月担任美国赛诺菲公司的临床科学家。在此之前，从2000年9月至2002年9月，她在辉瑞公司担任临床科学家。1993年5月，Ji博士从罗格斯大学新布朗斯威克研究生院、新泽西州立大学和美国罗伯特·伍德·约翰逊医学院生物医学科学研究生院联合提供的细胞生物学课程中获得了医学硕士学位。1986年8月，她在中国首都医学研究院获得医学博士学位。
- Ping Ji,serve as Adlai Nortye Ltd. director effective upon the completion of this offering. She has over 25 years of experience in biopharmaceutical drug development. Since July 2017, Dr. Ji served as the global safety leader at Kyowa Kirin Co., Ltd. in the United States. Before that, from August 2011 to July 2017, she served as the global safety leader at Bayer HealthCare Pharmaceuticals Inc. in the United States. Dr. Ji has also served as the medical safety lead at Taiho in the United States from December 2006 to July 2011, as a medical reviewer at Bristol-Myers Squibb Company in the United States from June 2004 to December 2006, and as a clinical scientist at Sanofi S.A. in the United States from September 2002 to June 2004. Prior to that, from September 2000 to September 2002, she worked as a clinical scientist at Pfizer Corporation. Dr. Ji obtained her master of medicine from the cell biology program offered jointly by Graduated School-New Brunswick at Rutgers, the state University of New Jersey and the UMDNJ-Graduate School of Biomedical Sciences at Robert Wood Johnson Medical School in the United States in May 1993. She obtained her doctor of medicine from Capital Institute of Medicine in the PRC in August 1986.
- Lars Erik Birgerson
-
Lars Erik Birgerson将担任Adlai Nortye Ltd.董事，自本次发行完成后生效。自2018年7月起担任Adlai Nortye USA INC总裁兼首席执行官，自2021年7月起担任Adlai Nortye Ltd.首席医疗官。Birgerson博士在制药行业拥有超过32年的经验。在加入Adlai Nortye Ltd.之前，Birgerson博士曾在瑞士巴塞尔的罗氏制药担任副总裁兼全球和美国医疗事务主管；在美国加利福尼亚州的基因泰克担任医疗事务副总裁；在美国新泽西州的BMS担任医疗事务高级副总裁。从2016年1月至今，伯格森博士担任美国新泽西州伯格森集团的总裁和高级顾问。自2016年2月起，Birgerson博士还担任迪卡斯公司的全球医学顾问。Birgerson博士分别于1977年6月和1990年6月在瑞典乌普萨拉的乌普萨拉大学获得医学博士和哲学博士学位。Birgerson博士自1984年12月14日以来一直是瑞典国家卫生和福利委员会认证的妇产科专家。此外，他于1980年2月19日被瑞典国家卫生和福利委员会认证为执业医师。
Lars Erik Birgerson,will serve as Adlai Nortye Ltd. director effective upon the completion of this offering. He has served as the president and chief executive officer of Adlai Nortye USA INC since July 2018 and has served as Adlai Nortye Ltd. chief medical officer since July 2021. Dr. Birgerson has more than 32 years of experience in the pharmaceutical industry. Prior to joining Adlai Nortye Ltd. , Dr. Birgerson served as the vice president and head of global and US medical affairs at Roche Pharmaceuticals in Basel, Switzerland; the vice president of medical affairs at Genentech in California, the United States; and the senior vice president of medical affairs at BMS in New Jersey, the United States. From January 2016 to date, Dr. Birgerson has served as the president and senior advisor of The Birgerson Group in New Jersey, the United States. Since February 2016, Dr. Birgerson has also served as the global medical consultant of Delcath Systems Inc. Dr. Birgerson received his Doctor of Medicine and doctorate of philosophy from Uppsala University at Uppsala, Sweden in June 1977 and June 1990 respectively. Dr. Birgerson has been a specialist of obstetrics and gynecology certified by the National Swedish Board of Health and Welfare since December 14, 1984. Further, he was certified as a licensed physician by the National Swedish Board of Health and Welfare in Sweden on February 19, 1980. - Lars Erik Birgerson将担任Adlai Nortye Ltd.董事，自本次发行完成后生效。自2018年7月起担任Adlai Nortye USA INC总裁兼首席执行官，自2021年7月起担任Adlai Nortye Ltd.首席医疗官。Birgerson博士在制药行业拥有超过32年的经验。在加入Adlai Nortye Ltd.之前，Birgerson博士曾在瑞士巴塞尔的罗氏制药担任副总裁兼全球和美国医疗事务主管；在美国加利福尼亚州的基因泰克担任医疗事务副总裁；在美国新泽西州的BMS担任医疗事务高级副总裁。从2016年1月至今，伯格森博士担任美国新泽西州伯格森集团的总裁和高级顾问。自2016年2月起，Birgerson博士还担任迪卡斯公司的全球医学顾问。Birgerson博士分别于1977年6月和1990年6月在瑞典乌普萨拉的乌普萨拉大学获得医学博士和哲学博士学位。Birgerson博士自1984年12月14日以来一直是瑞典国家卫生和福利委员会认证的妇产科专家。此外，他于1980年2月19日被瑞典国家卫生和福利委员会认证为执业医师。
- Lars Erik Birgerson,will serve as Adlai Nortye Ltd. director effective upon the completion of this offering. He has served as the president and chief executive officer of Adlai Nortye USA INC since July 2018 and has served as Adlai Nortye Ltd. chief medical officer since July 2021. Dr. Birgerson has more than 32 years of experience in the pharmaceutical industry. Prior to joining Adlai Nortye Ltd. , Dr. Birgerson served as the vice president and head of global and US medical affairs at Roche Pharmaceuticals in Basel, Switzerland; the vice president of medical affairs at Genentech in California, the United States; and the senior vice president of medical affairs at BMS in New Jersey, the United States. From January 2016 to date, Dr. Birgerson has served as the president and senior advisor of The Birgerson Group in New Jersey, the United States. Since February 2016, Dr. Birgerson has also served as the global medical consultant of Delcath Systems Inc. Dr. Birgerson received his Doctor of Medicine and doctorate of philosophy from Uppsala University at Uppsala, Sweden in June 1977 and June 1990 respectively. Dr. Birgerson has been a specialist of obstetrics and gynecology certified by the National Swedish Board of Health and Welfare since December 14, 1984. Further, he was certified as a licensed physician by the National Swedish Board of Health and Welfare in Sweden on February 19, 1980.
- Shaorong Liu
-
刘绍荣将担任Adlai Nortye Ltd.的独立董事，自本次发行完成后生效。刘先生在企业管理和咨询方面拥有大约15年的经验。自2008年4月起，刘先生一直担任上海智易企业管理咨询有限公司的管理合伙人和高级顾问。此外，刘先生还自2018年4月起担任江苏共创草业股份有限公司（上海证券交易所股票代码：605099）的独立非执行董事。刘先生于2012年9月在中欧国际工商学院获得工商管理硕士学位。
Shaorong Liu,will serve as Adlai Nortye Ltd. independent director effective upon the completion of this offering. Mr. Liu has approximately 15 years of experience in business management and consulting. Mr. Liu has been serving as the managing partner and senior consultant of Shanghai Zhiyi Enterprise Management Consulting Co., Ltd. since April 2008. Further, Mr. Liu has also been an independent non-executive director of Jiangsu CoCreation Grass Co., Ltd. (Shanghai Stock Exchange stock code: 605099) since April 2018. Mr. Liu obtained his master's degree in business administration from the China Europe International Business School in September 2012. - 刘绍荣将担任Adlai Nortye Ltd.的独立董事，自本次发行完成后生效。刘先生在企业管理和咨询方面拥有大约15年的经验。自2008年4月起，刘先生一直担任上海智易企业管理咨询有限公司的管理合伙人和高级顾问。此外，刘先生还自2018年4月起担任江苏共创草业股份有限公司（上海证券交易所股票代码：605099）的独立非执行董事。刘先生于2012年9月在中欧国际工商学院获得工商管理硕士学位。
- Shaorong Liu,will serve as Adlai Nortye Ltd. independent director effective upon the completion of this offering. Mr. Liu has approximately 15 years of experience in business management and consulting. Mr. Liu has been serving as the managing partner and senior consultant of Shanghai Zhiyi Enterprise Management Consulting Co., Ltd. since April 2008. Further, Mr. Liu has also been an independent non-executive director of Jiangsu CoCreation Grass Co., Ltd. (Shanghai Stock Exchange stock code: 605099) since April 2018. Mr. Liu obtained his master's degree in business administration from the China Europe International Business School in September 2012.
- Ming Lun Alan Tse
-
Ming Lun Alan Tse，担任Adlai Nortye Ltd.独立董事，自本次发行完成后生效。谢先生在财务管理和会计方面拥有20多年的经验。谢先生目前担任捷成资本有限公司的总经理和天鸽互动控股有限公司（香港交易所：1980）的独立非执行董事。在此之前，谢先生于2002年9月至2005年5月担任毕马威会计师，于2005年5月至2007年5月担任创科实业有限公司高级分析师。谢先生还曾于2007年9月至2009年8月在Next Horizon有限公司担任企业规划和发展高级经理，并于2009年9月至2011年10月在历峰亚太有限公司担任财务和行政部项目和业务发展经理。自2011年11月起，谢先生担任捷成汽车技术北京有限公司总经理。谢先生于2002年12月在香港大学取得会计和金融工商管理学士学位。自2005年12月以来，他一直是特许公认会计师公会（ACCA）的资深会员。
Ming Lun Alan Tse,serve as Adlai Nortye Ltd. independent director effective upon the completion of this offering. Mr. Tse has more than 20 years of experience in financial management and accounting. Mr. Tse currently serves as a general manager at Jebsen Capital Ltd. and the independent non-executive director of Tian Ge Interactive Holdings Ltd. (HKEx: 1980). Previously, Mr. Tse has served as an accountant at KPMG from September 2002 to May 2005, a senior analyst at Techtronic Industries Co., Ltd from May 2005 to May 2007. Mr. Tse has also served as a senior manager of corporate planning and development, a senior manager of corporate planning and development at Next Horizon Company Limited from September 2007 to August 2009, and a project and business development manager of finance and administration department at Richemont Asia Pacific Limited from September 2009 to October 2011. SinceNovember 2011, Mr. Tse has served as a general manager of Jebsen Automotive Technology Beijing Co., Ltd. Mr. Tse obtained his bachelor of business administration in accounting and finance from the University of Hong Kong in December 2002. He has been a fellow member of the Association of Chartered Certified Accountants (ACCA) since December 2005. - Ming Lun Alan Tse，担任Adlai Nortye Ltd.独立董事，自本次发行完成后生效。谢先生在财务管理和会计方面拥有20多年的经验。谢先生目前担任捷成资本有限公司的总经理和天鸽互动控股有限公司（香港交易所：1980）的独立非执行董事。在此之前，谢先生于2002年9月至2005年5月担任毕马威会计师，于2005年5月至2007年5月担任创科实业有限公司高级分析师。谢先生还曾于2007年9月至2009年8月在Next Horizon有限公司担任企业规划和发展高级经理，并于2009年9月至2011年10月在历峰亚太有限公司担任财务和行政部项目和业务发展经理。自2011年11月起，谢先生担任捷成汽车技术北京有限公司总经理。谢先生于2002年12月在香港大学取得会计和金融工商管理学士学位。自2005年12月以来，他一直是特许公认会计师公会（ACCA）的资深会员。
- Ming Lun Alan Tse,serve as Adlai Nortye Ltd. independent director effective upon the completion of this offering. Mr. Tse has more than 20 years of experience in financial management and accounting. Mr. Tse currently serves as a general manager at Jebsen Capital Ltd. and the independent non-executive director of Tian Ge Interactive Holdings Ltd. (HKEx: 1980). Previously, Mr. Tse has served as an accountant at KPMG from September 2002 to May 2005, a senior analyst at Techtronic Industries Co., Ltd from May 2005 to May 2007. Mr. Tse has also served as a senior manager of corporate planning and development, a senior manager of corporate planning and development at Next Horizon Company Limited from September 2007 to August 2009, and a project and business development manager of finance and administration department at Richemont Asia Pacific Limited from September 2009 to October 2011. SinceNovember 2011, Mr. Tse has served as a general manager of Jebsen Automotive Technology Beijing Co., Ltd. Mr. Tse obtained his bachelor of business administration in accounting and finance from the University of Hong Kong in December 2002. He has been a fellow member of the Association of Chartered Certified Accountants (ACCA) since December 2005.
- Cheguo Cai
-
蔡车国，担任Adlai Nortye Ltd.独立董事，自本次发行完成后生效。他在生物学和免疫学行业拥有超过17年的经验。蔡博士自2021年5月起担任深圳百克生物科技股份有限公司首席科学家，自2022年12月起担任杭州高等研究院教授。2017年2月至2022年11月，蔡博士担任武汉大学医学研究所和免疫学与元前沿科学中心教授。蔡博士分别于2015年4月至2017年1月和2011年10月至2015年3月担任中国科学院上海生物化学与细胞生物学研究所副教授和博士后研究员。在此之前，他于2010年10月至2011年9月在美国杜兰大学担任博士后研究员。2005年8月至2007年8月，任中国科学院上海巴斯德研究所研究助理。蔡博士分别于2002年7月和2005年7月在厦门大学获得生物学学士学位和硕士学位。2010年7月在中国科学院上海巴斯德研究所获得微生物学博士学位。
Cheguo Cai,serve as Adlai Nortye Ltd. independent director effective upon the completion of this offering. He has more than 17 years of experience in the biology and immunology industries. Dr. Cai has served as chief scientist at Shenzhen Beike Biotech Co., Ltd. since May 2021 and as professor at Hangzhou Institute for Advanced Study, UCAS since December 2022. From February 2017 to November 2022, Dr. Cai served as professor at the Medical Research Institute and Frontier Science Center for Immunology and Meta, Wuhan University. Dr. Cai served as associate professor and postdoctoral fellow at Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences since April 2015 to January 2017 and since October 2011 to March 2015, respectively. Before that, from October 2010 to September 2011, he served as postdoctoral fellow at Tulane University in the United States. From August 2005 to August 2007, he served as research assistant at Institut Pasteur of Shanghai, Chinese Academy of Sciences. Dr. Cai obtained his bachelor's degree and master's degree in biology in Xiamen University in July 2002 and July 2005, respectively. He obtained his doctoral degree in microbiology in Institut Pasteur of Shanghai, Chinese Academy of Sciences in July 2010. - 蔡车国，担任Adlai Nortye Ltd.独立董事，自本次发行完成后生效。他在生物学和免疫学行业拥有超过17年的经验。蔡博士自2021年5月起担任深圳百克生物科技股份有限公司首席科学家，自2022年12月起担任杭州高等研究院教授。2017年2月至2022年11月，蔡博士担任武汉大学医学研究所和免疫学与元前沿科学中心教授。蔡博士分别于2015年4月至2017年1月和2011年10月至2015年3月担任中国科学院上海生物化学与细胞生物学研究所副教授和博士后研究员。在此之前，他于2010年10月至2011年9月在美国杜兰大学担任博士后研究员。2005年8月至2007年8月，任中国科学院上海巴斯德研究所研究助理。蔡博士分别于2002年7月和2005年7月在厦门大学获得生物学学士学位和硕士学位。2010年7月在中国科学院上海巴斯德研究所获得微生物学博士学位。
- Cheguo Cai,serve as Adlai Nortye Ltd. independent director effective upon the completion of this offering. He has more than 17 years of experience in the biology and immunology industries. Dr. Cai has served as chief scientist at Shenzhen Beike Biotech Co., Ltd. since May 2021 and as professor at Hangzhou Institute for Advanced Study, UCAS since December 2022. From February 2017 to November 2022, Dr. Cai served as professor at the Medical Research Institute and Frontier Science Center for Immunology and Meta, Wuhan University. Dr. Cai served as associate professor and postdoctoral fellow at Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences since April 2015 to January 2017 and since October 2011 to March 2015, respectively. Before that, from October 2010 to September 2011, he served as postdoctoral fellow at Tulane University in the United States. From August 2005 to August 2007, he served as research assistant at Institut Pasteur of Shanghai, Chinese Academy of Sciences. Dr. Cai obtained his bachelor's degree and master's degree in biology in Xiamen University in July 2002 and July 2005, respectively. He obtained his doctoral degree in microbiology in Institut Pasteur of Shanghai, Chinese Academy of Sciences in July 2010.
高管简历
中英对照 | 中文 | 英文- Yang Lu
杨璐是Adlai Nortye Ltd.集团的联合创始人，自2006年起担任Adlai Nortye Ltd.董事。目前，他还担任Adlai Nortye有限公司首席执行官和Adlai Nortye有限公司董事会主席。卢先生在制药业有20年的经验。在创立Adlai Nortye有限公司之前，卢先生于2003年4月至2004年3月在Hybio制药有限公司工作。卢先生于2002年7月获得厦门大学生物技术学士学位，并于2012年9月获得中欧国际工商学院EMBA-Executive工商管理硕士学位。
Yang Lu,co-founded Adlai Nortye Ltd. group and has served as Adlai Nortye Ltd. director since 2006. Currently he also serves as Adlai Nortye Ltd. chief executive officer and the chairman of Adlai Nortye Ltd. board of directors. Mr. Lu has 20 years of experience in the pharmaceutical industry. Prior to founding Adlai Nortye Ltd. company, Mr. Lu worked at Hybio Pharmaceutical Co., Ltd from April 2003 to March 2004. Mr. Lu obtained his bachelor's degree in biotechnology from Xiamen University in July 2002, and his EMBA-Executive Master of Business Administration from China Europe International Business School in September 2012.- 杨璐是Adlai Nortye Ltd.集团的联合创始人，自2006年起担任Adlai Nortye Ltd.董事。目前，他还担任Adlai Nortye有限公司首席执行官和Adlai Nortye有限公司董事会主席。卢先生在制药业有20年的经验。在创立Adlai Nortye有限公司之前，卢先生于2003年4月至2004年3月在Hybio制药有限公司工作。卢先生于2002年7月获得厦门大学生物技术学士学位，并于2012年9月获得中欧国际工商学院EMBA-Executive工商管理硕士学位。
- Yang Lu,co-founded Adlai Nortye Ltd. group and has served as Adlai Nortye Ltd. director since 2006. Currently he also serves as Adlai Nortye Ltd. chief executive officer and the chairman of Adlai Nortye Ltd. board of directors. Mr. Lu has 20 years of experience in the pharmaceutical industry. Prior to founding Adlai Nortye Ltd. company, Mr. Lu worked at Hybio Pharmaceutical Co., Ltd from April 2003 to March 2004. Mr. Lu obtained his bachelor's degree in biotechnology from Xiamen University in July 2002, and his EMBA-Executive Master of Business Administration from China Europe International Business School in September 2012.
- Lars Erik Birgerson
Lars Erik Birgerson将担任Adlai Nortye Ltd.董事，自本次发行完成后生效。自2018年7月起担任Adlai Nortye USA INC总裁兼首席执行官，自2021年7月起担任Adlai Nortye Ltd.首席医疗官。Birgerson博士在制药行业拥有超过32年的经验。在加入Adlai Nortye Ltd.之前，Birgerson博士曾在瑞士巴塞尔的罗氏制药担任副总裁兼全球和美国医疗事务主管；在美国加利福尼亚州的基因泰克担任医疗事务副总裁；在美国新泽西州的BMS担任医疗事务高级副总裁。从2016年1月至今，伯格森博士担任美国新泽西州伯格森集团的总裁和高级顾问。自2016年2月起，Birgerson博士还担任迪卡斯公司的全球医学顾问。Birgerson博士分别于1977年6月和1990年6月在瑞典乌普萨拉的乌普萨拉大学获得医学博士和哲学博士学位。Birgerson博士自1984年12月14日以来一直是瑞典国家卫生和福利委员会认证的妇产科专家。此外，他于1980年2月19日被瑞典国家卫生和福利委员会认证为执业医师。
Lars Erik Birgerson,will serve as Adlai Nortye Ltd. director effective upon the completion of this offering. He has served as the president and chief executive officer of Adlai Nortye USA INC since July 2018 and has served as Adlai Nortye Ltd. chief medical officer since July 2021. Dr. Birgerson has more than 32 years of experience in the pharmaceutical industry. Prior to joining Adlai Nortye Ltd. , Dr. Birgerson served as the vice president and head of global and US medical affairs at Roche Pharmaceuticals in Basel, Switzerland; the vice president of medical affairs at Genentech in California, the United States; and the senior vice president of medical affairs at BMS in New Jersey, the United States. From January 2016 to date, Dr. Birgerson has served as the president and senior advisor of The Birgerson Group in New Jersey, the United States. Since February 2016, Dr. Birgerson has also served as the global medical consultant of Delcath Systems Inc. Dr. Birgerson received his Doctor of Medicine and doctorate of philosophy from Uppsala University at Uppsala, Sweden in June 1977 and June 1990 respectively. Dr. Birgerson has been a specialist of obstetrics and gynecology certified by the National Swedish Board of Health and Welfare since December 14, 1984. Further, he was certified as a licensed physician by the National Swedish Board of Health and Welfare in Sweden on February 19, 1980.- Lars Erik Birgerson将担任Adlai Nortye Ltd.董事，自本次发行完成后生效。自2018年7月起担任Adlai Nortye USA INC总裁兼首席执行官，自2021年7月起担任Adlai Nortye Ltd.首席医疗官。Birgerson博士在制药行业拥有超过32年的经验。在加入Adlai Nortye Ltd.之前，Birgerson博士曾在瑞士巴塞尔的罗氏制药担任副总裁兼全球和美国医疗事务主管；在美国加利福尼亚州的基因泰克担任医疗事务副总裁；在美国新泽西州的BMS担任医疗事务高级副总裁。从2016年1月至今，伯格森博士担任美国新泽西州伯格森集团的总裁和高级顾问。自2016年2月起，Birgerson博士还担任迪卡斯公司的全球医学顾问。Birgerson博士分别于1977年6月和1990年6月在瑞典乌普萨拉的乌普萨拉大学获得医学博士和哲学博士学位。Birgerson博士自1984年12月14日以来一直是瑞典国家卫生和福利委员会认证的妇产科专家。此外，他于1980年2月19日被瑞典国家卫生和福利委员会认证为执业医师。
- Lars Erik Birgerson,will serve as Adlai Nortye Ltd. director effective upon the completion of this offering. He has served as the president and chief executive officer of Adlai Nortye USA INC since July 2018 and has served as Adlai Nortye Ltd. chief medical officer since July 2021. Dr. Birgerson has more than 32 years of experience in the pharmaceutical industry. Prior to joining Adlai Nortye Ltd. , Dr. Birgerson served as the vice president and head of global and US medical affairs at Roche Pharmaceuticals in Basel, Switzerland; the vice president of medical affairs at Genentech in California, the United States; and the senior vice president of medical affairs at BMS in New Jersey, the United States. From January 2016 to date, Dr. Birgerson has served as the president and senior advisor of The Birgerson Group in New Jersey, the United States. Since February 2016, Dr. Birgerson has also served as the global medical consultant of Delcath Systems Inc. Dr. Birgerson received his Doctor of Medicine and doctorate of philosophy from Uppsala University at Uppsala, Sweden in June 1977 and June 1990 respectively. Dr. Birgerson has been a specialist of obstetrics and gynecology certified by the National Swedish Board of Health and Welfare since December 14, 1984. Further, he was certified as a licensed physician by the National Swedish Board of Health and Welfare in Sweden on February 19, 1980.
- Kaiyang Tang
唐凯阳，自2018年8月起担任Adlai Nortye Ltd.高级副总裁兼全球临床运营主管。唐博士在制药行业拥有超过20年的经验。1990年至1997年，他在伊丽莎白综合医学中心担任研究协调员。从1997年到1999年，唐博士在科文司担任全球现场协调员和临床研究助理。从1999年到2003年，唐博士在辉瑞公司担任高级临床项目经理。2003年至2007年，他在Pliva Inc.担任临床项目负责人和医学监督员。2007年至2010年，他在Hutchison MediPharma Ltd.担任副总裁兼临床和监管事务主管。2010年至今，他在Generon Inc.担任首席医疗官、临床和监管主管。唐博士于1986年在中国首都医学研究所获得医学博士学位。他于1999年在新泽西州立大学罗格斯大学获得MBA学位。
Kaiyang Tang,has served as Adlai Nortye Ltd. senior vice president and global head of clinical operations since August 2018. Dr. Tang has more than 20 years of experience in the pharmaceutical industry. From 1990 to 1997, he served as study coordinator at Elizabeth General Medical Center. From 1997 to 1999, Dr. Tang served as global site coordinator and clinical research associate at Covance Inc. Dr. Tang served as senior clinical program manager at Pfizer Corporation from 1999 to 2003. From 2003 to 2007, he served as clinical program leader and medical monitor at Pliva Inc. From 2007 to 2010, he served as vice president and head of clinical and regulatory affairs at Hutchison MediPharma Ltd. From 2010 to date, he has served as chief medical officer, head of clinical and regulatory at Generon Inc. Dr. Tang obtained his medical doctor degree from Capital Institute of Medicine in the PRC in 1986. He obtained his MBA degree from Rutgers, the State University of New Jersey in 1999.- 唐凯阳，自2018年8月起担任Adlai Nortye Ltd.高级副总裁兼全球临床运营主管。唐博士在制药行业拥有超过20年的经验。1990年至1997年，他在伊丽莎白综合医学中心担任研究协调员。从1997年到1999年，唐博士在科文司担任全球现场协调员和临床研究助理。从1999年到2003年，唐博士在辉瑞公司担任高级临床项目经理。2003年至2007年，他在Pliva Inc.担任临床项目负责人和医学监督员。2007年至2010年，他在Hutchison MediPharma Ltd.担任副总裁兼临床和监管事务主管。2010年至今，他在Generon Inc.担任首席医疗官、临床和监管主管。唐博士于1986年在中国首都医学研究所获得医学博士学位。他于1999年在新泽西州立大学罗格斯大学获得MBA学位。
- Kaiyang Tang,has served as Adlai Nortye Ltd. senior vice president and global head of clinical operations since August 2018. Dr. Tang has more than 20 years of experience in the pharmaceutical industry. From 1990 to 1997, he served as study coordinator at Elizabeth General Medical Center. From 1997 to 1999, Dr. Tang served as global site coordinator and clinical research associate at Covance Inc. Dr. Tang served as senior clinical program manager at Pfizer Corporation from 1999 to 2003. From 2003 to 2007, he served as clinical program leader and medical monitor at Pliva Inc. From 2007 to 2010, he served as vice president and head of clinical and regulatory affairs at Hutchison MediPharma Ltd. From 2010 to date, he has served as chief medical officer, head of clinical and regulatory at Generon Inc. Dr. Tang obtained his medical doctor degree from Capital Institute of Medicine in the PRC in 1986. He obtained his MBA degree from Rutgers, the State University of New Jersey in 1999.
- Wei Zhang
张伟于2021年6月加入Adlai Nortye Ltd.，担任Adlai Nortye Ltd.首席财务官。2014年7月至2015年7月，张女士在野村国际担任分析师。她于2015年11月9日至2021年6月12日在高盛高盛（亚洲）有限责任公司担任公司金融部执行董事。张女士于2013年4月在美国伊利诺伊斯卫斯理大学获得会计和经济学学士学位。她于2014年7月获得英国牛津大学金融经济学理学硕士学位。
Wei Zhang,joined Adlai Nortye Ltd. in June 2021 as Adlai Nortye Ltd. chief financial officer. From July 2014 to July 2015, Ms. Zhang served as an analyst at Nomura International Plc. She was in the role of executive director within the Corporate Finance Department of Goldman Sachs (Asia) L.L.C. and was employed by the firm from November 9, 2015 to June 12, 2021. Ms. Zhang obtained her Bachelor of Arts in accounting and economics from Illinois Wesleyan University in the United States in April 2013. She obtained a Master of Science in financial economics from University of Oxford in the United Kingdom in July 2014.- 张伟于2021年6月加入Adlai Nortye Ltd.，担任Adlai Nortye Ltd.首席财务官。2014年7月至2015年7月，张女士在野村国际担任分析师。她于2015年11月9日至2021年6月12日在高盛高盛（亚洲）有限责任公司担任公司金融部执行董事。张女士于2013年4月在美国伊利诺伊斯卫斯理大学获得会计和经济学学士学位。她于2014年7月获得英国牛津大学金融经济学理学硕士学位。
- Wei Zhang,joined Adlai Nortye Ltd. in June 2021 as Adlai Nortye Ltd. chief financial officer. From July 2014 to July 2015, Ms. Zhang served as an analyst at Nomura International Plc. She was in the role of executive director within the Corporate Finance Department of Goldman Sachs (Asia) L.L.C. and was employed by the firm from November 9, 2015 to June 12, 2021. Ms. Zhang obtained her Bachelor of Arts in accounting and economics from Illinois Wesleyan University in the United States in April 2013. She obtained a Master of Science in financial economics from University of Oxford in the United Kingdom in July 2014.
- Victoria Elizabeth Demby
Victoria Elizabeth Demby，自2022年3月起担任Adlai Nortye Ltd.高级副总裁兼全球监管事务主管。Demby博士在各个职能领域拥有30多年的制药经验。1992年1月至1996年8月，德姆比博士在惠氏-艾斯特研究所担任副研究员，2001年5月至2002年1月在杜邦制药公司担任高级研究员，2002年3月至2003年4月在Quest Pharmaceutical Services担任高级研究员。2003年5月至2008年7月，她在GSK，Inc.担任临床前部门运输组组长。之后，Demby博士于2008年8月至2010年2月在BMS担任提交文件小组高级研究研究员，并于2010年3月至2012年9月担任全球监管战略和安全副主任。后来，Demby博士于2012年9月至2019年1月在MSD担任董事，并于2019年1月至2019年5月担任执行董事。之后，她于2019年5月至2019年10月在Greenwich Biosciences担任高级董事。最近，Demby博士自2019年11月起在葛兰素史克公司担任全球监管团队的执行董事和团队负责人，并自2021年7月起担任全球监管事务临时副总裁。Demby博士于1991年5月在佛蒙特大学获得生物化学学士学位，并于2001年5月在堪萨斯大学获得药理学和毒理学博士学位。
Victoria Elizabeth Demby,has served as Adlai Nortye Ltd. senior vice president and global head of regulatory affairs since March 2022. Dr. Demby has more than 30 years of pharmaceutical experience in various functional areas. From January 1992 to August 1996, Dr. Demby served at Wyeth-Ayerst Research as associate scientist.She later served at Dupont Pharmaceuticals as senior research investigator from May 2001 to January 2002, and then at Quest Pharmaceutical Services as senior research investigator from March 2002 to April 2003. From May 2003 to July 2008, she served at GSK, Inc. as section head of transport group in the preclinical department. After that, Dr. Demby served at BMS as senior research investigator of submission documents group from August 2008 to February 2010, as associate director of global regulatory strategy and safety from March 2010 to September 2012. Later, Dr. Demby served at MSD as a director from September 2012 to January 2019, as an executive director from January 2019 to May 2019. Then, she worked at Greenwich Biosciences as a senior director from May 2019 to October 2019. Recently, Dr. Demby has served at GlaxoSmithKline, Inc as executive director and team leader of global regulatory team since November 2019 and has also served as interim vice president of global regulatory affairs since July 2021. Dr. Demby obtained her bachelor's degree in biochemistry in University of Vermont in May 1991 and her doctoral degree in pharmacology and toxicology in University of Kansas in May 2001.- Victoria Elizabeth Demby，自2022年3月起担任Adlai Nortye Ltd.高级副总裁兼全球监管事务主管。Demby博士在各个职能领域拥有30多年的制药经验。1992年1月至1996年8月，德姆比博士在惠氏-艾斯特研究所担任副研究员，2001年5月至2002年1月在杜邦制药公司担任高级研究员，2002年3月至2003年4月在Quest Pharmaceutical Services担任高级研究员。2003年5月至2008年7月，她在GSK，Inc.担任临床前部门运输组组长。之后，Demby博士于2008年8月至2010年2月在BMS担任提交文件小组高级研究研究员，并于2010年3月至2012年9月担任全球监管战略和安全副主任。后来，Demby博士于2012年9月至2019年1月在MSD担任董事，并于2019年1月至2019年5月担任执行董事。之后，她于2019年5月至2019年10月在Greenwich Biosciences担任高级董事。最近，Demby博士自2019年11月起在葛兰素史克公司担任全球监管团队的执行董事和团队负责人，并自2021年7月起担任全球监管事务临时副总裁。Demby博士于1991年5月在佛蒙特大学获得生物化学学士学位，并于2001年5月在堪萨斯大学获得药理学和毒理学博士学位。
- Victoria Elizabeth Demby,has served as Adlai Nortye Ltd. senior vice president and global head of regulatory affairs since March 2022. Dr. Demby has more than 30 years of pharmaceutical experience in various functional areas. From January 1992 to August 1996, Dr. Demby served at Wyeth-Ayerst Research as associate scientist.She later served at Dupont Pharmaceuticals as senior research investigator from May 2001 to January 2002, and then at Quest Pharmaceutical Services as senior research investigator from March 2002 to April 2003. From May 2003 to July 2008, she served at GSK, Inc. as section head of transport group in the preclinical department. After that, Dr. Demby served at BMS as senior research investigator of submission documents group from August 2008 to February 2010, as associate director of global regulatory strategy and safety from March 2010 to September 2012. Later, Dr. Demby served at MSD as a director from September 2012 to January 2019, as an executive director from January 2019 to May 2019. Then, she worked at Greenwich Biosciences as a senior director from May 2019 to October 2019. Recently, Dr. Demby has served at GlaxoSmithKline, Inc as executive director and team leader of global regulatory team since November 2019 and has also served as interim vice president of global regulatory affairs since July 2021. Dr. Demby obtained her bachelor's degree in biochemistry in University of Vermont in May 1991 and her doctoral degree in pharmacology and toxicology in University of Kansas in May 2001.